ANI Pharmaceuticals takes over rights to Testosterone Gel 1%
Upon commercialization, ANI will pay Teva up to $5 million at a rate of 5% of the consideration received by ANI as a result of commercial sale of
Upon commercialization, ANI will pay Teva up to $5 million at a rate of 5% of the consideration received by ANI as a result of commercial sale of
LCS Group’s exclusive license is part of a unique strategic collaboration with the intellectual property’s owner, Lucerne Biosciences, with further details of the collaboration soon to be announced.
This is one of the largest such screens of its type to date and will drive understanding of the biological mechanisms underlying these conditions and their complications. The
Discovered by BioCryst, BCX7353 is a novel, selective inhibitor of plasma kallikrein in development for prevention of attacks in patients with hereditary angioedema (HAE). BioCryst has successfully completed
Italy is the 23rd country to authorize CEL-SCI’s Phase 3 trial for patient enrollment. Having surpassed its originally planned milestone of receiving authorization to conduct the Phase 3
The new Securel patent application is entitled "Multimodal Abuse Resistant and Extended Release Opioid Formulations." Once granted, the patent is expected to be valid until at least 2028.
Esmocard is indicated for supraventricular tachycardia (except for pre-excitation syndromes) and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in
The rare pediatric disease designation augments the Orphan Drug designation granted by the FDA and announced by Fibrocell in June 2014 for FCX-007 to treat dystrophic epidermolysis bullosa
The study showed the investigational cancer immunotherapy MPDL3280A (anti-PDL1) doubled the likelihood of survival (overall survival [OS]; hazard ratio [HR]=0.47) in people whose cancer expressed the highest levels
EIB has granted the loan facility to support the research and development of novel vaccines against Ebola and other infectious diseases as well as cancer immunotherapies. The loan